1. Home
  2. ANIX vs ACOG Comparison

ANIX vs ACOG Comparison

Compare ANIX & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.59

Market Cap

135.3M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$5.52

Market Cap

130.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
ACOG
Founded
1982
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.3M
130.9M
IPO Year
1987
N/A

Fundamental Metrics

Financial Performance
Metric
ANIX
ACOG
Price
$3.59
$5.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$9.00
$18.00
AVG Volume (30 Days)
353.5K
84.0K
Earning Date
01-09-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,427,199.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$143.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.07
$3.75
52 Week High
$5.46
$11.54

Technical Indicators

Market Signals
Indicator
ANIX
ACOG
Relative Strength Index (RSI) 36.66 35.86
Support Level $4.20 $5.66
Resistance Level $5.46 $6.74
Average True Range (ATR) 0.42 0.41
MACD -0.06 -0.01
Stochastic Oscillator 3.40 0.00

Price Performance

Historical Comparison
ANIX
ACOG

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: